Researchers at the University of Ottawa and the Institute of Hydrobiology of the Chinese Academy of Sciences have discovered a new role for reproductive hormone secretoneurin (SN) and, for the first ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
Restricting calorie intake in species such as mice, rhesus monkeys, and fruit flies has been shown to extend their lifespans.
Our immune system works all the time to protect us from harmful bacteria, viruses, and injuries. It is a complex system made ...
EMPAVELI®(pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in CanadaApproval supported ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...
DeepRare, an agentic AI system integrating 40 specialised tools, outperformed medical specialists in identifying rare conditions in a head-to-head study published in Nature. For millions of people ...
Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, including for rare genetic conditions that the ...
Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, including for rare genetic conditions that the ...
Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart’s Phase III results are promising, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results